Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions
- PMID: 35550257
- DOI: 10.1016/j.molcel.2022.04.019
Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions
Abstract
Many cancers are characterized by gene fusions encoding oncogenic chimeric transcription factors (TFs) such as EWS::FLI1 in Ewing sarcoma (EwS). Here, we find that EWS::FLI1 induces the robust expression of a specific set of novel spliced and polyadenylated transcripts within otherwise transcriptionally silent regions of the genome. These neogenes (NGs) are virtually undetectable in large collections of normal tissues or non-EwS tumors and can be silenced by CRISPR interference at regulatory EWS::FLI1-bound microsatellites. Ribosome profiling and proteomics further show that some NGs are translated into highly EwS-specific peptides. More generally, we show that hundreds of NGs can be detected in diverse cancers characterized by chimeric TFs. Altogether, this study identifies the transcription, processing, and translation of novel, specific, highly expressed multi-exonic transcripts from otherwise silent regions of the genome as a new activity of aberrant TFs in cancer.
Keywords: chimeric transcription factors; long non-coding RNAs; sarcomas; tumor-specific peptides; tumor-specific transcripts.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J. Vibert, O.S., J. Vigneau, M.G., C.C., J.J.W., and O.D. are named inventors of a patent application on neotranscripts. All other authors declare that they have no competing interests.
Comment in
-
Oncogenic transcription factors and neogenes: New opportunities for cancer immunotherapy?Mol Cell. 2022 Jul 7;82(13):2353-2355. doi: 10.1016/j.molcel.2022.06.006. Mol Cell. 2022. PMID: 35803214
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources